Abstract
Drug hypersensitivity reactions are unpredictable adverse drug reactions. ey manifest either within 1-6 h following drug intake (immediate reactions) with mild to life-threatening symptoms of anaphylaxis, or several hours to days later (delayed reactions), primarily as exanthematous eruptions. It is not always possible to detect involvement of the immune system (allergy). Waiving diagnostic tests can result in severe reactions on renewed exposure on the one hand, and to unjusti ed treatment restrictions on the other. With this guideline, experts from various specialist societies and institutions have formulated recommendations and an algorithm for the diagnosis of allergies. e key principles of diagnosing allergic/hypersensitivity drug reactions are presented. Where possible, the objective is to perform allergy diagnostics within 4 weeks-6 months following the reaction. A clinical classi cation of symptoms based on the morphology and time course of the reaction is required in order to plan a diagnostic work-up. In the case of typical symptoms of a drug hypersensitivity reaction and unequivocal ndings from validated skin and/or laboratory tests, a reaction can be attributed to a trigger with sucient con dence. However, skin and laboratory tests are o en negative or insu ciently reliable. In such cases, controlled provocation testing is required to clarify drug reactions. is method is reliable and safe when attention is paid to indications and contraindications and performed under appropriate medical supervision. e results of the overall assessment are discussed with the patient and documented in an "allergy passport" in order to ensure targeted avoidance in the future and allow the use of alternative drugs where possible.
Introduction
Whilst type-A adverse drug reactions (ADR) are caused by known pharmacological or toxic reactions, hypersensitivity drug reactions are caused by individual predisposing factors in the patient and are essentially unpredictable (type-B reactions) [1] . Drug allergy is distinct from a non-immunological drug hypersensitivity reaction (Tab. 1).
All cases of suspected hypersensitivity reactions associated with the use of drugs in any age group should undergo diagnostic investigation with the aim of identifying the trigger and possibly the underlying pathomechanism, assessing the patient's risk for further reactions, and advising the patient accordingly on this risk [2] . Dispensing with a diagnostic work-up can result in severe reactions on renewed exposure on the one hand, and to unjusti ed restrictions in terms of treatment options on the other.
e DGAKI and the DDG assigned the working group Arzneimittelallergie ("drug allergy") with the task of updating the current version of the guideline [1] . Following constitutive meetings on 11 October 2012 and 5 September 2013, K. Brockow, B. Przybilla, and H. Merk compiled a dra version of the new guideline by updating and revising the existing guideline [2] . Together with experts from other specialist societies and institutions largely involved in the treatment of patients with drug hypersensitivity reactions, recommendations were developed based on literature searches, an assessment of participants' experiences, and theoretical considerations. At a consensus conference held on 15 April 2014, each recommendation was discussed and agreed on in a structured consensus-nding process under neutral moderation in order to solve open decision-making problems and to provide a nal assessment of the recommendations.
is guideline is addressed to all physicians, as well as other professionals working in the medical eld, involved in the diagnosis of and counseling on drug hypersensitivity reactions in patients of all age groups. e general principles of clarifying drug hypersensitivity reactions are presented. It is beyond the scope of this guideline to provide details on diagnostic methods or speci c procedures in the case of hypersensitivity reactions to individual drugs or drug groups, or on rare diseases induced by drug hypersensitivity.
De nition and classi cation
De nitions for the classi cation of ADR are given in Tab. 1 [1] . Diagnostic allergy tests are only useful in allergic or non-allergic hypersensitivity reactions, not, however, in pharmacological or toxic ADR.
Clinical classi cation on the basis of morphology, chronology, and time course is helpful for further diagnostic planning and permits the di erentiation of hypersensitivity reactions based on the time course (Tab. 2) [1, 3] .
Diagnostic methods
Investigations should be performed by an experienced allergist or at a specialized allergy center. Knowledge of drugs that frequently elicit speci c hypersensitivity reactions is essential for diagnostic planning in order to be able to assess the likelihood with which a drug has caused a reaction. Patient history as well as skin, in vitro, and provocation tests are used to identify the trigger. A precise description and classi cation of the original reaction is of utmost importance. Any diagnostic work-up should take into consideration the particular features of the individual case as well as the diagnostic options available (Fig. 1) [4] .
Every e ort should be made to perform diagnostic allergy testing within 4 weeks-6 months a er the resolution of symptoms. ere is evidence that successful detection of hypersensitivity several years a er the reaction is less frequent [5, 6] . Diagnostic testing for allergy in patients with no previous history of drug hypersensitivity ("prophetic testing") is not bene cial [7] .
Patient history and ndings clinical manifestation
e diagnostic success rate is higher in patients presenting during the acute phase of a reaction, since it is possible at that point to establish di erential diagnoses, classify clinical manifestations, and reliably interpret the course of symptoms in relation to drug use. Creating a timeline diagram is recommended in cases where multiple drugs are taken. Typical time intervals between rst drug intake and symptom onset are shown in Tab. 3. Although information provided by the patient, as well as all available medical records relating to the reaction (e. g., discharge letter, medical chart, anesthetic chart) need to be consulted, these are sometimes unreliable. A standardized questionnaire to collect relevant information is available [8, 9] . A test plan is formulated on the basis of all available information.
To this end, the following information should be documented: A. Clinical manifestation: -Documentation of clinical manifestations and/or organ systems involved, e. g., skin, respiratory 
Skin tests
Skin tests are carried out in the context of hypersensitivity reactions involving symptoms consistent with allergy in order to determine a sensitization [10, 11] . As yet, there is no uniform standard for skin testing with drugs. e European Network on Drug Allergy (ENDA) methods, which are currently being investigated in studies, are recommended [11] . In cases where provocation tests are not possible, e. g., as with muscle relaxants, skin testing plays a particularly important role in the diagnosis of allergy [12, 13] .
However, diagnostically useful skin test reactions occur only in some patients with hypersensitivity reactions. Test substances in high concentrations can cause reactions even in healthy individuals. It is [14] . Where appropriate, natural rubber latex allergy should be excluded. In extremely rare cases, skin testing with the trigger of a hypersensitivity reaction can cause systemic, occasionally life-threatening reactions. e physician performing the skin test, as well as nursing sta must be prepared to deal with potential emergency situations [11, 15, 16, 17] .
De novo sensitization as a result of skin testing is possible, whereby this risk depends on the substance tested, its concentration, and the test method used.
erefore, intradermal tests and patch tests should only be performed with the drug suspected of triggering a reaction or relevant alternatives.
e indication for skin testing with non-standardized substances must be established according to particularly strict criteria. Tests with incremental increases in the test substance concentration (threshold tests, e. g., 1 : 1000, 1 : 100, 1 : 10) can reduce the risk of severe allergic reactions during cutaneous testing. 
In vitro investigations
Particularly in the case of negative skin tests or severe life-threatening reactions, laboratory investigations can be helpful, most notably when provocation testing is not possible or where the skin test itself poses a risk, as in anaphylactic reactions to β-lactam antibiotics, for instance [18, 19] .
In vitro diagnosis with drugs
Tests to measure speci c immunoglobulin E (IgE) antibodies to various drugs are available (Tab. 5).
Although cellular tests are sometimes helpful, they are only available at a limited number of centers and can cause problems in early childhood due to the large volumes of blood required [20, 21] .
-Validated tests to detect speci c IgE (sIgE) antibodies in serum are available for only a small number of drugs (Tab. 5; most notably β-lactam antibiotics); other than that, there are no standardized and evaluated in vitro procedures. -Other immunological laboratory methods [e. g., basophile histamine release test, basophile activation test, cysteinyl-leukotriene release test (cellular antigen stimulation test, CAST), lymphocyte transformation test, lymphocyte activation test, Enzyme-Linked ImmunoSpot assay (ELISpot test)] may be helpful in selected cases; however, they should not be used as a rule in routine practice, not least since standardization is not guaranteed. -It is not possible to conclusively detect or exclude drug hypersensitivity solely on the basis of in vitro tests. In vitro test results can only be interpreted in conjunction with patient history/clinical ndings and possibly in vivo tests.
Additional in vitro investigations
-In the presence of relevant clinical symptoms, measurement of drug-metabolizing enzymes to detect metabolic disorders associated with hypersensitivity to certain drugs [e. g., dihydropyrimidine dehydrogenase (methotrexate), thiopurine S-methyltransferase (azathioprine)] -Where appropriate, pharmacogenetic investigations, e. g., human leukocyte antigen (HLA) status, in the case of abacavir use in Caucasians (B*5701) or carbamazepine use in Asians (B*1502) -Where appropriate, mast cell mediator detection (in particular tryptase) to con rm anaphylaxis preferably 1-2 h a er the start of a reaction and for comparison with baseline tryptase value ( a er 2-3 days)
Provocation tests
Provocation tests are indicated when the drug triggering hypersensitivity cannot be identi ed with su cient reliability on the basis of history, skin testing, and in vitro investigations and when the benet of information obtained from prvovocation testing outweighs the risks [22] . is is o en the case. Particularly in the case of suspected reactions to substances in drug groups that are essential or that cannot be permanently avoided (e. g., analgesics, antibiotics, local anesthetics), provocation tests also serve to identify tolerated drugs (alternative preparations in the case of possible drug cross-reactivity). Drug provocation testing is indicated for the purposes of [22] : -Excluding hypersensitivity when the history is unclear -Con rming the diagnosis when the history is suggestive but includes negative, unconvincing, or unavailable results from other diagnostic tests -Excluding cross-reactivity of related drugs e patient should be informed about the goal of diagnostic testing, the risks involved, the alternatives, as well as the test procedure, including the use of placebo. Informed consent should be given in writing.
Medical supervision during the follow-up period, with the possibility of providing prompt intensive medical care if required, should be maintained for as long as severe reactions (e. g., anaphylaxis) can be expected. For this reason, provocation tests likely to cause systemic reactions should be performed in an in-patient setting equipped to provide immediate emergency care (experienced medical and nursing sta , appropriate drugs and technical equipment). Determining the procedure of drug provocation testing should always remain a case-by-case medical decision that takes numerous individual factors into consideration (e. g., type of drug, estimated likelihood of a reaction, expected severity of the reaction, patient expectations/anxiety).
e basic principle of provocation testing is to administer substances in the form in which they caused hypersensitivity reactions in the past. Oral administration can be attempted with some substances, even though a di erent mode of administration was originally used (e. g., i.m., i. v., rectal). In some forms of reaction a local test at the reaction site in the sense of a "localized provocation test" is possible (e. g., in xed drug eruptions with patch testing in loco). As a basic rule, in-patient provocation tests should be performed in a placebo-controlled manner, since a large number of reactions are also seen with placebo tests. 
Assessment
-Provocation test results should be assessed preferably on the basis of objective parameters; nevertheless, subjective symptoms should also be recorded. -Symptoms, as well as the evolution of a reaction over time, should be documented and, where possible, quantitative parameters measured (e. g., blood pressure, respiratory parameters, serum tryptase levels). -In the case of drug reactions, further tests should be performed with active ingredients and excipients, where available -If a preparation of the suspected active substance as produced by a center's own pharmacy dispensary fails to induce a reaction, provocation should then be performed with the drug preparation used in the patient history. -In the case of a reaction to placebo, perform reverse placebo provocation tests where appropriate (Tab. 6) Note: A negative provocation test does not reliably exclude hypersensitivity. In particular, e ects exerted by the disease originally treated (e. g., viral infections), drug interactions, or a reduction in sensitivity over time can be responsible for false-negative results. e negative predictive value of negative provocation testing to various drugs is > 95 % in most cases, and the severity of the rare reactions seen under renewed re-exposure despite tolerance in provocation tests was mostly mild [24, 25] .
A reduction in the degree of sensitivity over time can be expected with allergic reactions that lie far in the past. In such cases, although a provocation test may be negative, it may have a "booster" e ect.
erefore, in the case of a long interval between a reaction and testing, re-provocation testing a er 4-6 weeks may be considered.
Contraindications
e following contraindications exist for tests with suspected culprit drugs, as well as for tests with alternative preparations where cross-reactivity is assumed. In speci c cases (e. g., suspected reactions to excipients), provocation testing may be justi ed, despite contraindications, in order to identify an active substance urgently required for treatment purposes. An individual risk-bene t assessment is essential in all cases.
-Pregnancy and breastfeeding -Hypersensitivity reactions that may be beyond medical control (e. g., uncontrolled asthma, agranulocytosis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, vasculitis, hepatopathy). -Diseases or the use of drugs that carry an increased risk despite essentially controllable reactions (e. g., drugs contraindicated in anaphylaxis: severe cardiovascular disease, severe asthma, β-blocker use). -Inadequate compliance, lack of understanding of the procedure on the part of the patient.
Overall assessment e nal assessment of ndings needs to be made by taking not only results from skin, in vitro, and provocations tests but also, more particularly, the history of the clinical reaction into consideration. Although drug hypersensitivity cannot be reliably ruled out even by applying all available test methods, they do makeenable better risk assessment easier.
e result of the overall assessment is discussed with the patient and documented. Ideally, an allergy passport is issued, representing a medical document.
is provides information on the reaction type and substances/preparations not tolerated, along with information on possible cross-reactivities. Possible (tested) alternative substances/preparations, as well as the maximum single and cumulative dose, should be stated (e.g., "paracetamol tolerated up to a single dose of 500 mg [cumulative 800 mg] in oral provocation"). Mention should also be made of the fact
